Cargando…

Amenamevir: Studies of Potential CYP3A‐Mediated Pharmacokinetic Interactions With Midazolam, Cyclosporine, and Ritonavir in Healthy Volunteers

Amenamevir (formerly ASP2151) is a helicase‐primase inhibitor being developed for the treatment of herpesvirus infection. Amenamevir is both a substrate and inducer of cytochrome P450 (CYP) 3A4. Three studies were done in healthy volunteers to investigate potential CYP3A pharmacokinetic interactions...

Descripción completa

Detalles Bibliográficos
Autores principales:	Adeloye, Temitope, Sahgal, Omair, Puri, Adeep, Warrington, Steve, Endo, Takamasa, Dennison, Jeremy, Johnston, Atholl
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6585933/ https://www.ncbi.nlm.nih.gov/pubmed/30044899 http://dx.doi.org/10.1002/cpdd.586

Ejemplares similares

Amenamevir: Studies of Potential CYP2C8‐ and CYP2B6‐Mediated Pharmacokinetic Interactions With Montelukast and Bupropion in Healthy Volunteers
por: Dennison, Jeremy, et al.
Publicado: (2018)

Pharmacokinetic Evaluation of the Interactions of Amenamevir (ASP2151) with Ketoconazole, Rifampicin, Midazolam, and Warfarin in Healthy Adults
por: Kusawake, Tomohiro, et al.
Publicado: (2017)

Pharmacokinetics and Dialyzability of a Single Oral Dose of Amenamevir, an Anti-Herpes Drug, in Hemodialysis Patients
por: Tsuruoka, Shuichi, et al.
Publicado: (2020)

Correction to: Pharmacokinetics and Dialyzability of a Single Oral Dose of Amenamevir, an Anti-Herpes Drug, in Hemodialysis Patients
por: Tsuruoka, Shuichi, et al.
Publicado: (2020)

Pharmacokinetic Interaction Between Prasugrel and Ritonavir in Healthy Volunteers
por: Ancrenaz, Virginie, et al.
Publicado: (2013)

Pharmacokinetics and Safety of Amenamevir in Healthy Subjects: Analysis of Four Randomized Phase 1 Studies
por: Kusawake, Tomohiro, et al.
Publicado: (2017)

The effect of piperine on midazolam plasma concentration in healthy volunteers, a research on the CYP3A-involving metabolism
por: Rezaee, Mohammad Mahdi, et al.
Publicado: (2014)

Amenamevir, a Helicase-Primase Inhibitor, for the Optimal Treatment of Herpes Zoster
por: Shiraki, Kimiyasu, et al.
Publicado: (2021)

A 1-Year Survey of Zoster-Associated Pain after Amenamevir Treatment
por: Kawashima, Makoto, et al.
Publicado: (2022)

Composite midazolam and 1′-OH midazolam population pharmacokinetic model for constitutive, inhibited and induced CYP3A activity
por: Wiebe, Sabrina T., et al.
Publicado: (2020)

Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers
por: Dickinson, Laura, et al.
Publicado: (2009)

Aseptic Meningitis after Amenamevir Treatment for Herpes Zoster in the First Branch of the Trigeminal Nerve
por: Itoh, Kazuhiro, et al.
Publicado: (2022)

Absorption, Distribution, Metabolism, and Excretion of the Novel Helicase-Primase Inhibitor, Amenamevir (ASP2151), in Rodents
por: Ohtsu, Yoshiaki, et al.
Publicado: (2018)

An Open‐Label, Single‐Dose, Human Mass Balance Study of Amenamevir in Healthy Male Adults
por: Kato, Kota, et al.
Publicado: (2018)

Unexpected Hepatotoxicity of Rifampin and Saquinavir/Ritonavir in Healthy Male Volunteers
por: Schmitt, Christophe, et al.
Publicado: (2009)

Potential Hepatotoxicity of Efavirenz and Saquinavir/Ritonavir Coadministration in Healthy Volunteers
por: Jamois, Candice, et al.
Publicado: (2009)

Population Pharmacokinetic Model Characterizing 24-Hour Variation in the Pharmacokinetics of Oral and Intravenous Midazolam in Healthy Volunteers
por: van Rongen, A, et al.
Publicado: (2015)

The Efficacy of Amenamevir for the Treatment of Disseminated Herpes Zoster Complicated with Probable Varicella-zoster Pneumonia in an Immunocompromised Patient
por: Kobayashi, Hiroki, et al.
Publicado: (2021)

Inhibitory effects of Triphala on CYP isoforms in vitro and its pharmacokinetic interactions with phenacetin and midazolam in rats
por: Nontakham, Jannarin, et al.
Publicado: (2022)

Semiphysiologically based pharmacokinetic model for midazolam and CYP3A mediated metabolite 1‐OH‐midazolam in morbidly obese and weight loss surgery patients
por: Brill, MJE, et al.
Publicado: (2015)

Drug-Drug Interaction Analysis of Pyronaridine/Artesunate and Ritonavir in Healthy Volunteers
por: Morris, Carrie A., et al.
Publicado: (2012)

Inhibition of CYP3A-mediated Midazolam Metabolism by Kaempferia Parviflora
por: Kashiwabuchi, Yumika, et al.
Publicado: (2022)

Inhibitory Effects of Baicalin on the Expression and Activity of CYP3A Induce the Pharmacokinetic Changes of Midazolam in Rats
por: Tian, Xin, et al.
Publicado: (2013)

Drug‐Drug Interaction Study of Apixaban with Cyclosporine and Tacrolimus in Healthy Volunteers
por: Bashir, Babar, et al.
Publicado: (2018)

Pomegranate Juice does not Affect the Bioavailability of Cyclosporine in Healthy Thai Volunteers
por: Anlamlert, Wirin, et al.
Publicado: (2020)

Effects of Tipranavir, Darunavir, and Ritonavir on Platelet Function, Coagulation, and Fibrinolysis in Healthy Volunteers
por: Kort, Jens J, et al.
Publicado: (2011)

Bioavailability and Safety of a New Highly Concentrated Midazolam Nasal Spray Compared to Buccal and Intravenous Midazolam Treatment in Chinese Healthy Volunteers
por: Wang, Hui, et al.
Publicado: (2022)

Evidence of CYP3A Allosterism In Vivo: Analysis of Fluconazole and Midazolam Interaction
por: Yang, Jing, et al.
Publicado: (2011)

The Mechanism-Based Inactivation of CYP3A4 by Ritonavir: What Mechanism?
por: Loos, Nancy H. C., et al.
Publicado: (2022)

A randomized, double-blind, single-dose study (LAVENDER) to assess the safety, tolerability, pharmacokinetics, and immunogenicity of a combined infusion of ABP 980 and pertuzumab in healthy subjects
por: Hanes, Vladimir, et al.
Publicado: (2021)

WCN23-0117 PAXLOVID ( NIRMATRELVIR/RITONAVIR ) AND CYCLOSPORIN IN A KIDNEY TRANSPLANT PATIENT WITH COVID-19 INFECTION
por: Then, R.F., et al.
Publicado: (2023)

The Effects of Weak and Strong CYP3A Induction by Rifampicin on the Pharmacokinetics of Five Progestins and Ethinylestradiol Compared to Midazolam
por: Wiesinger, Herbert, et al.
Publicado: (2020)

Effect of CYP3A4*22, CYP3A5*3, and CYP3A Combined Genotypes on Cyclosporine, Everolimus, and Tacrolimus Pharmacokinetics in Renal Transplantation
por: Moes, D J A R, et al.
Publicado: (2014)

Equivalence and interchangeability of narrow therapeutic index drugs in organ transplantation
por: Johnston, Atholl
Publicado: (2013)

A Single Dose of Baicalin Has No Clinically Significant Effect on the Pharmacokinetics of Cyclosporine A in Healthy Chinese Volunteers
por: Liu, Ruijuan, et al.
Publicado: (2019)

Midazolam Pharmacokinetics in Morbidly Obese Patients Following Semi-Simultaneous Oral and Intravenous Administration: A Comparison with Healthy Volunteers
por: Brill, Margreke J. E., et al.
Publicado: (2014)

Propofol, midazolam, vancomycin and cyclosporine therapeutic drug monitoring in extracorporeal membrane oxygenation circuits primed with whole human blood
por: Lemaitre, Florian, et al.
Publicado: (2015)

A Semi-Mechanistic Metabolism Model of CYP3A Substrates in Pregnancy: Predicting Changes in Midazolam and Nifedipine Pharmacokinetics
por: Quinney, S K, et al.
Publicado: (2012)

The Pharmacokinetics of the CYP3A Substrate Midazolam in Morbidly Obese Patients Before and One Year After Bariatric Surgery
por: Brill, Margreke J., et al.
Publicado: (2015)

The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients
por: Lunde, Ingrid, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_9ktl4lvmk7pipi20dqoi7jqarc